Trial Profile
Patient reported outcomes in renal transplant patients tolerating GI symptoms converted to myfortic (EC-MPS)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2008
Price :
$35
*
At a glance
- Drugs Mycophenolate sodium (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2008 New trial record.